The ability of glycogen synthase kinase-3 (GSK-3) to phosphorylate insulin receptor substrate-1 (IRS-1) is a potential inhibitory mechanism for insulin resistance in type 2 diabetes. However, the serine site(s) phosphorylated by GSK-3 within IRS-1 had not been yet identified. 
Insulin resistance, commonly defined as the inability of peripheral tissues to respond normally to physiological concentrations of insulin, is considered one of the earliest changes associated with the onset of type 2 diabetes (1-3). Although a great deal of progress has been made toward understanding insulin transduction pathways (2, 4, 5) , the molecular basis underlying insulin resistance is not understood fully. IRS-1 1 proteins are important signaling molecules that become tyrosyl-phosphorylated by the insulin receptor tyrosine kinase and, simultaneously, initiate signaling cascades via recruitment of Src homology 2 domain-containing proteins, including the p85 regulatory subunit of phosphatidylinositol 3-kinase, Grb-2, SHP2, and Nck (6, 7) . Decreased phosphorylation of IRS-1 on tyrosine is usually associated with insulin resistance (5, 8, 9) . However, because IRS-1 is also phosphorylated mainly on serine and threonine residues (10) , it has been proposed that this type of phosphorylation integrates a negative feedback signal to attenuate insulin signaling (11) (12) (13) (14) (15) (16) (17) . Indeed, enhanced phosphorylation of IRS-1 on serine/threonine residues was shown to be associated with insulin resistance and type 2 diabetes (8, 18 -20) . Several specific phosphorylation sites within IRS-1 were identified. Phosphorylation of Ser 307 is enhanced by tumor necrosis factor-␣ and phosphorylated by c-Jun N-terminal kinase (JNK; 19, 21) and inhibitor B kinase (IKK␤) (22) . Phosphatidylinositol 3-kinase/murine target of rapamycin (mTOR)-dependent kinase(s) was shown to promote IRS-1 phosphorylation at serines 307, 612, and 632 (23) . In vivo increased phosphorylation of Ser 789 was found in diabetic liver (18) . PKC isoforms were shown to enhance serine phosphorylation of IRS-1 as well (24 -27) . Specifically, phorbol 12-myristate 13-acetate-sensitive PKC isoforms were implicated in the enhanced phosphorylation of Ser 612 (24) , and PKC-was shown to phosphorylate serines 570 and 318 (28, 29) . Phosphorylation of serines 632, 662, and 731 was shown to be associated with desensitization of insulin signaling (30, 31) , and nutrient-dependent stimulation enhanced the phosphorylation of Ser 302 (32) ; subsequently, increased phosphorylation of this serine was detected in diabetic liver (19) . Finally, other protein kinases, such as casein kinase 2, Akt, and 5ЈAMP-activated protein kinase have been implicated in serine phosphorylation of IRS-1 as well (33) (34) (35) .
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase that has been implicated in multiple receptor-mediated intracellular processes (for review, see Refs. 36 and 37). We showed previously that GSK-3 promotes the phosphorylation of IRS-1 exclusively on serine residues, which, in turn, attenuated insulin signaling in cultured cells (14) . Additional studies pointed to the contribution of GSK-3 in insulin resistance and type 2 diabetes: elevated levels of GSK-3 activity were detected in diabetic tissues (38, 39) and, when treated with selective GSK-3 inhibitors, provoked insulin-like effects in vitro and in vivo (40 -44) . We hypothesized that hyperactive GSK-3 may enhance serine phosphorylation of IRS-1, decreasing its ability to be tyrosyl-phosphorylated (by the insulin receptor, IR) (14) . However, the specific IRS-1 serine sites phosphorylated by GSK-3 were not identified. In this work, we used deletion and mutation techniques, together with specific phosphoantibody to identify serine site(s) within IRS-1 phosphorylated by GSK-3. Here, we show that GSK-3 phosphorylates Ser 332 of IRS-1 and that mutation at this site enhances insulin-induced tyrosine phosphorylation of IRS-1. We bring evidence that Ser 336 is the priming site usually required for GSK-3 substrates (45, 46) . Finally, we demonstrate the physiological relevance of Ser 332 phosphorylation with specific phospho-IRS-1 antibody.
MATERIALS AND METHODS
Plasmids and Transient Transfection-The rat IRS-1 and ⌬N-IRS-1 cDNAs subcloned into eukaryotic expression vector pCMVHIS were kindly provided by Morris F. White (Joslin Diabetes Center, Boston) (21) . PTB-1 and PTB-2 constructs coding for residues 1-320 and 1-350 of IRS-1, respectively, were generated by PCR, using primers 5Ј-cgcggaagcttatggcgagccctccggatacc-3Ј (PTB-1 sense), 5Ј-gccgcgaagctttgaaggaacctggttt-3Ј (PTB-1 antisense), and 5Ј-gccgcgaagcttcgtgggtcctgttggtgc-3Ј (PTB-2 antisense). Respective fragments were digested with HindIII and subcloned into pCMV4 expression vector (47) . Mutations at serines 332, 336, 340, 343, and 345 were introduced into IRS-1 or PTB-2 constructs, using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). All mutations and fragments were sequenced to confirm the presence of mutations. The sequence of mutagenic oligonucleotides is available from the authors upon request.
Cells and Transfections-HEK-293 cells were grown in Dulbecco's modified Eagle's medium containing 25 mM glucose, 10% fetal calf serum, 2 mM glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin. HEK-293 cells were transiently transfected with IRS-1 or PTB constructs (5 g each), using the calcium phosphate method as described previously (48) . Chinese hamster ovary cells overexpressing the IR (CHO-IR cells), kindly provided by Yehiel Zick (Weizmann Institute of Science), were transiently transfected with IRS-1 constructs using FuGENE 6 (Roche Applied Science), according to the manufacturer's instructions. Expression of IRS-1 mutant proteins was verified by Western blot analysis, using IRS-1-specific antibody raised against either the C terminus (14) or the N terminus of IRS-1 (Santa-Cruz Biotechnology, Inc., Santa Cruz, CA). C2C12 myoblasts were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and differentiated in Dulbecco's modified Eagle's medium supplemented with 10% horse serum. Myotubes were used 4 -6 days later.
Cell Extraction and GSK-3 Assays-Cells were lysed in ice-cold buffer G (20 mM Tris, pH 7.5, 10 mM ␤-glycerophosphate, 10% glycerol, 1 mM EGTA, 1 mM EDTA, 50 mM NaF, 5 mM NaPP i , 0.5 mM orthovanadate, 1 mM benzamidine, 5 g/ml leupeptin, 25 g/ml aprotinin, 500 nM microcysteine LR, and 1% Triton X-100). Cell extracts were centrifuged for 20 min at 15,000 ϫ g. Supernatants were collected, and equal amounts of protein (30 g) were boiled with SDS sample buffer and subjected to gel electrophoresis (7.5-12% polyacrylamide gel), transferred to nitrocellulose membranes, and immunoblotted with specific antibodies, anti-phosphotyrosine antibody, PY99 (Santa-Cruz Biotechnology), anti-phospho-PKB antibody (Ser 473 or Thr 308 ), and PKB antibody (Cell Signaling), according to the manufacturers' protocols. In a different set of experiments, IRS-1 or PTB proteins were immunoprecipitated from cell extracts with specific antibodies against IRS-1 (described above). GSK-3 kinase assays were performed in the immunoprecipitate complex. The reaction mixture contained 50 mM Tris, pH 7.4, 10 mM magnesium acetate, [␥-32 P[ATP (100 M, 0.5 Ci/assay), 0.01% ␤-mercaptoethanol, 10 nM microcysteine and was incubated with 0.5 g of purified recombinant GSK-3 (48) for 15 min at 30°C. The reactions were stopped by the addition of SDS sample buffer and then boiled and subjected to gel electrophoresis. Gels were dried and autoradiographed.
Treatment with Protein Serine/Threonine Phosphates Type 2A (PP2A)-IRS-1 was immunoprecipitated from CHO cells overexpressing IRS-1 (CHO-IRS-1), as described in the previous section. The immunoprecipitate was treated with PP2A, according to the manufacturer's protocols (Upstate Biotechnology, Inc.) for 40 min at 30°C. After extensive washes with 50 mM Tris, pH 7.4, 1 mM dithiothreitol, 5% glycerol, and 10 nM LR microcysteine (Calbiochem), purified recombinant GSK-3 was added to the immunoprecipitate together with [␥-
32 P]ATP in conditions similar to those described above. The reactions were stopped by the addition of SDS sample buffer and then boiled and subjected to gel electrophoresis. Gels were dried and autoradiographed.
Treatment with Phosphatase-IRS-1 was immunoprecipitated from HEK-293 cells overexpressing IRS-1 as described in the previous section. The immunoprecipitate was treated with phosphatase (Cell Signaling) according to the manufacturer's protocols, for 30 min at 30°C. The immunoprecipitates were boiled with SDS sample buffer and subjected to gel electrophoresis. VDG. Arginine was added to the N terminus of the peptide to enable binding to p81 paper, and threonine 330 was replaced with glycine. Purified GSK-3 was incubated in a reaction mixture of 50 mM Tris, pH 7.3, 10 mM magnesium acetate, [␥-32 P]ATP (100 M, 0.5 Ci/assay), and 0.01% ␤-mercaptoethanol, together with 200 M peptides for 5, 10, or 15 min at 30°C. The reactions were stopped, spotted on P-81 paper, (Whatman), washed with phosphoric acid, and counted for radioactivity, as described previously (14) .
Phosphorylation of IRS-1 Peptide by GSK-3-Two
Antibody-Polyclonal antibody directed against phosphorylated IRS-1 (at Ser 332 ) was generated by Bethyl Laboratories, Inc. (Montgomery, TX). In brief, two rabbits were immunized with synthetic phosphoSer 332 based on the amino acid sequence around Ser 332 coupled to keyhole limpet hemocyanin. Sera were pooled and stripped of antibodies that reacted with nonphosphorylated versions of the peptide using a nonphosphopeptide affinity column. The reactive material was eluted from a phosphopeptide affinity column at low pH. The affinity-purified antibody was tested by enzyme-linked immunosorbent assay and by immunoblot analysis (dilution 1:1,000), as described under "Results."
Statistics and graphics analyses were performed by Origin 6.0 Professional software.
RESULTS

Identification of the Major GSK-3 Phosphorylation Site in the IRS-1 Fragment PTB-2 and Full-length IRS-1-Direct identification of IRS-1 phosphorylation sites is difficult (see "Discussion"
). Therefore, we used a molecular biology approach. The N-terminal domain of IRS-1 was shown to be important for its interaction with the IR (49, 50), so we first used a deleted mutant of IRS-1 lacking residues 140 -541 (⌬N-IRS-1 (21)) (see Fig. 1A ). Wild-type (WT) IRS-1 or ⌬N-IRS-1 constructs were transiently expressed in HEK-293 cells, and their protein levels were determined by Western blot analysis (Fig. 1B, lower  panel) . Equal amounts of expressed IRS-1 proteins were immunoprecipitated from cell extracts with specific antibody and subjected to a "hot" GSK-3 phosphorylation assay. As shown in Fig. 1B (upper panel) , WT-IRS-1 was phosphorylated readily by GSK-3, whereas the ⌬N-IRS-1 mutant was weakly phosphorylated by the enzyme. This led us to conclude that GSK-3 phosphorylation site(s) are located within residues 140 -541. The amino acid sequence of 140 -541 was analyzed to identify potential sites of phosphorylation by GSK-3. A putative GSK-3 consensus sequence (SXXXS) was located at a serine cluster harboring residues 332, 336, and 340 (see Fig. 2A ). Accordingly, two IRS-1 fragments were generated: PTB-1, coding for amino acids 1-320 (which lacked this serine cluster); and PTB-2, coding for residues 1-350 (which included this serine cluster), as illustrated in Fig. 1A . PTB-1 and PTB-2 were expressed transiently in HEK-293 cells and detected by Western blot analysis as proteins with an apparent molecular mass of 36 and 39 kDa, respectively (Fig. 1C, lower panel) . Equal amounts of PTB-1 and PTB-2 were immunoprecipitated from cell lysates with specific IRS-1 antibody and were subjected to GSK-3 phosphorylation. As shown in Fig. 1C (upper panel) , GSK-3 phosphorylated PTB-2, but not PTB-1. These results indicated that GSK-3 phosphorylation site(s) reside within amino acids 320 -350 and support our speculation that serines 332, 336, and 340 are the sites involved in GSK-3 phosphorylation.
Site-specific Mutagenesis Demonstrates the Role of Serines 332 and 336 in GSK-3-mediated Phosphorylation of IRS-1-To
determine further whether serines 332, 336, and 340 are GSK-3 phosphorylation sites ( Fig. 2A) , we mutated these sites to alanine within PTB-2 (i.e. S332A
PTB-2 , S336A PTB-2 ,
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S340A PTB-2 ). Two additional sites, serines 343 and 345, were also mutated to alanine to examine their possible role as "priming sites" (as explained earlier). The PTB-2 mutants were expressed in HEK-293 cells, and experiments similar to those described above were performed. As shown in Fig. 2B , mutation at serines 332 and 336 prevented the phosphorylation by GSK-3. On the other hand, the mutants S340 PTB-2 , S343A PTB-2 , and S345A PTB-2 were phosphorylated by GSK-3 (Fig. 2, B and  C) . Taken together, it appears that serines 332 and 336 are the sites involved in GSK-3 phosphorylation. Notably, this consensus site is highly conserved among human rat and mouse (Fig. 2D) .
Because GSK-3 has a unique requirement for phosphorylation at the ϩ4 position of its site (i.e. recognition motif: 2 where S 1 is the phosphorylation site and S 2 is the prephosphorylated priming site (45, 46, 51)), we assume that Ser 336 is the priming site phosphorylated by a different kinase. This was investigated further and will be discussed later.
After establishing serines 332 and 336 as the consensus sites required for GSK-3 phosphorylation in the PTB-2 fragment, we examined whether this also applies to full-length IRS-1. WT and IRS-1 mutants (S332A IRS-1 , S336A IRS-1 , and a double mutant S332A/S336A IRS-1 ) were expressed transiently in HEK-293 cells. Expression levels of WT IRS-1 and mutants were determined by Western blot analysis (Fig. 3,  lower panel) . Equal amounts of IRS-1 proteins were immunoprecipitated from cell extracts with specific antibody and subjected to GSK-3 phosphorylation. Indeed, none of the three mutants was phosphorylated by GSK-3 (Fig. 3, upper  panel) . As observed for PTB-2, S340A
IRS-1 was phosphorylated by GSK-3, ruling out the involvement of Ser 340 in GSK-3 phosphorylation (data not shown).
Serine 336 Is a Priming Site-
The following experiments examined whether Ser 336 serves as a priming site for GSK-3. Treatment of IRS-1 with the serine/threonine phosphatase PP2A significantly reduced the ability of GSK-3 to phosphorylate IRS-1, indicating that GSK-3 requires prephosphorylation of IRS-1 (Fig. 4A) . Next, we generated two synthetic peptides based on IRS-1 sequence: a phosphorylated peptide RREGGMS 332 RPAS 336 (p)VDG and its nonphosphorylated version. The peptides were subjected to in vitro phosphorylation by GSK-3 in the presence of [␥-32 P]ATP. As can be evaluated from Fig. 4B, only IRS-1 ) were transiently expressed in CHO-IR cells, which had been stimulated with 100 nM insulin. Expression levels of IRS-1 mutants were evaluated by Western blot analysis (Fig. 5A, bottom panel) , and lysates with equal amounts of IRS-1 proteins were subjected to immunoblot analysis using anti-phosphotyrosine antibody. As can be seen from Fig. 5A , insulin-induced tyrosine phosphorylations of IRS-1 were enhanced in S332A IRS-1 and S336A IRS-1 compared with WT-IRS-1. Notably, this effect was much stronger in the double mutant S332A/336A IRS-1 , even in resting conditions, where tyrosine levels were much above than that of WT-IRS-1. We next examined the insulin-mediated activation of the IRS-1-downstream target PKB in cells expressing S332A/ 336A IRS-1 . PKB phosphorylation on serine 473 and 308 (both of which sites are important for PKB activation (52)) was 2 The numbering of IRS-1 refers to the rat sequence.
FIG. 1. Phosphorylation of IRS-1-deleted mutant and IRS-1 fragments by GSK-3. A, WT and ⌬N-IRS-1 mutant (21) constructs are shown along with IRS-1 fragments PTB-1 and PTB-2. B, WT-IRS-1 and the ⌬N-IRS-1 mutant were transiently expressed in HEK-293 cells. Expression of proteins was determined by Western blot analysis using specific IRS-1 antibody as described under "Materials and Methods" (lower panel). Equal amounts of protein were immunoprecipitated from cell extracts and subjected to in vitro phosphorylation with GSK-3 using [␥-32 P]ATP as described under "Materials and Methods." Phosphorylated IRS-1 proteins are indicated (upper panel). C, PTB-1 and PTB-2 were transiently expressed in HEK-293 cells. Expression of proteins was determined by Western blot (IB) analysis using specific IRS-1 antibody as described under "Materials and Methods" (lower panel). Equal amounts of protein were immunoprecipitated from cell extracts with specific IRS-1 antibodies as described and subjected to in vitro phosphorylation with GSK-3 using [␥-32 P]ATP. Phosphorylated PTB proteins are indicated (upper panel).
enhanced significantly (Fig. 5B) , indicating that blockage of serine 332 and 336 phosphorylation enhances insulin signaling.
Serine 332 Is Phosphorylated in Cultured Cells and Is Sensitive to GSK-3-
A polyclonal antibody directed against the sequence surrounding phosphorylated Ser 332 in IRS-1 was generated and is termed here ␣pSer 332 -IRS-1. The specificity of the antibody was tested in immunoblot analysis of WT-IRS-1, which was phosphorylated by GSK-3 in vitro. In this experiment, the protein was immunoprecipitated from cell extract of HEK-293 cells that transiently expressed WT-IRS-1. The immunoprecipitate was then subjected to in vitro phosphorylation by GSK-3 in "cold" conditions. Reactions were separated on gel electrophoresis and immunoblotted with ␣pSer 332 -IRS-1. As can be evaluated from Fig. 6A , ␣pSer 332 -IRS-1 antibody reacted strongly with the GSK-3-treated IRS-1 compared with the nontreated samples. Furthermore, ␣pIRS-1 332 weakly detected IRS-1 that was first treated with phosphatase (Fig. 6B) . The ␣pSer 332 -IRS-1 antibody was also tested in immunoblot analyses of IRS-1 and PTB-2 mutants. The antibody reacted strongly with the wild-type proteins. However, S332A was not detected by the antibody (Fig. 6, C and D) . Finally, we examined whether GSK-3 is involved in cellular Ser 332 phosphorylation. WT-IRS-1 was expressed transiently in HEK-293 cells, and cells were treated with lithium, a known GSK-3 inhibitor (53). Immunoblot analyses with ␣pSer 332 -IRS-1 indicated that phosphorylation of Ser 332 was reduced upon treatment with lithium (Fig. 6E) . In contrast, expression of GSK-3 together with WT-IRS-1 enhanced Ser 332 phosphorylation (Fig. 6F) . In another set of experiments we examined the effect of lithium on the phosphorylation of endogenous IRS-1 in C2C12 myotubes. As shown in , and S332A/336A IRS-1 were transiently expressed in HEK-293 cells. Expression of proteins was verified by Western blot (IB) analysis using specific IRS-1 antibody as described under "Materials and Methods" and indicated that equal amounts of IRS-1 proteins were expressed (lower panel). IRS-1 proteins were immunoprecipitated from equal amount of cell extracts using specific IRS-1 antibodies and subjected to in vitro phosphorylation with GSK-3 in the presence of [␥- 
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together, these data strongly suggest that GSK-3 is a physiological regulator of Ser 332 phosphorylation of IRS-1. Finally, we examined the effect of insulin on the phosphorylation of Ser 332 . Treatment of CHO-IR cells expressing IRS-1 with insulin did not alter the phosphorylation of Ser 332 (Fig. 6H) . Thus, it appears that inhibition of GSK-3 by insulin does not affect IRS-1 serine phosphorylation.
DISCUSSION
Serine/threonine phosphorylation of IRS-1 has been increasingly recognized as a negative feedback regulator mechanism for insulin signaling. The protein kinase GSK-3 was shown to phosphorylate IRS-1 (14) . In addition, GSK-3 participates in insulin signaling as a downstream target inhibited by insulin (54, 55) and contributes to insulin resistance (14, 39) . Thus, GSK-3-mediated phosphorylation of IRS-1 may be an important mechanism in insulin resistance. However, the sites phosphorylated by GSK-3 had not been identified previously. It is difficult to identify GSK-3 phosphorylation sites within IRS-1 because the protein is heavily phosphorylated on serine residues (10, 14) . Moreover, GSK-3 has a special requirement of prephosphorylation for its target recognition (45, 46) , thus, further complicating the direct identification of the target site(s). Therefore, we employed a molecular biology approach to identify these sites. By using an N-terminal deleted IRS-1 mutant and two fragments of the protein (PTB-1 and PTB-2), we were able to locate GSK-3-phosphorylation site(s) within the region 320 -350 amino acids. This segment contained serines 332, 336, and 340, which lie within the GSK-3 consensus motif (SXXXS(p) where S(p) is usually prephosphorylated) and which are highly conserved in human, rat, and mouse (Fig.  2D) . Point mutation analyses indicated that mutation at serines 332 and 336 prevented GSK-3 phosphorylation of IRS-1. The requirement that GSK-3 substrates are prephosphorylated at the ϩ4 position (45, 46, 51) implicated Ser 336 as the priming site. This was confirmed by the following experiments. First, dephosphorylation of IRS-1 prevented GSK-3 phosphorylation. Second, phosphopeptide derived from the relevant IRS-1 sequence (where Ser 336 is phosphorylated) was readily phosphorylated by GSK-3 compared with the nonphosphorylated peptide (Fig. 4B) . Finally, we present a new specific anti-phospho-Ser 332 IRS-1 antibody and demonstrate the physiological relevance of the phosphorylation of this site.
The important result in our studies is that mutations at both serines 332 and 336 dramatically enhanced tyrosine phosphorylation of IRS-1 in both resting and insulin-stimulated conditions. This effect was demonstrated when each serine was 
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mutated separately, albeit to a lower extent. The latter observation probably means that phosphorylation of both serines 332 and 336 is important for an "effective" disruptive activity of IRS-1 signaling, namely, decreased ability to be tyrosyl-phosphorylated by the IR. This may present an example for hierarchical regulation: as long as Ser 336 is not phosphorylated, GSK-3-inhibitory function remains limited. Interestingly, recent work has reported similar observations where the disruptive effect of JNK on the IR/IRS-1 was dependent on the phosphorylation of both serines 307 and 302 (20) . Taken together these results further strengthen the role of GSK-3 in attenuating insulin signaling via serine phosphorylation of IRS-1 and explain, at least in part, that the insulin mimetic effect provoked by selective GSK-3 inhibitors (40 -44) is probably because of reduced Ser 332 phosphorylation of IRS-1. The mechanisms by which phosphorylation of serines 332 and 336 inhibits IRS-1 tyrosine phosphorylation is not fully clear. Given that those sites are found in close proximity to the PTB domain, which is 
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important in facilitating IR-IRS-1 interaction, their phosphorylation may disrupt this interactions and thus inhibit subsequent IRS-mediated signaling (28, 56, 57) . Alternatively, phosphorylation of those sites might recruit signaling molecules, which sterically inhibit interactions between the PTB domain of IRS-1 and the NPEY motif of the IR, preventing tyrosine phosphorylation of IRS-1 by the IR kinase (58, 59) . The additional strength of our studies is the establishment of a new specific phospho-IRS-1 antibody, ␣pSer 332 -IRS-1. Immunoblots with the antibody confirmed the physiological significance of this type of phosphorylation in cultured cells. Furthermore, based on the observation that treatment with GSK-3 inhibitor lithium specifically decreased the phosphorylation of Ser 332 , whereas overexpression of GSK-3 enhanced the phosphorylation of Ser 332 (Fig. 6 , E and F) we concluded that GSK-3 is involved in cellular phosphorylation of serine 332. Interestingly, in contrast to lithium, insulin did not reduce Ser 332 phosphorylation (Fig. 6H ). This may be explained by the fact that lithium induced prolonged inhibition of GSK-3 while insulin had a transient and rapid effect on GSK-3 activity (54), and this is probably not sufficient to decrease Ser 332 phosphorylation. On the other hand, abnormal elevated GSK-3 activity may cause up-regulation in Ser 332 phosphorylation (as demonstrated in Fig. 6F ), thus contributing to insulin resistance.
In summary, we identified Ser 332 as a GSK-3 phosphorylation site in IRS-1. These results provide insight into the role of GSK-3 as a negative feedback regulator of insulin signaling, permitting a more detailed analysis of this pathway under normal and pathophysiological conditions.
